期刊文献+

促红细胞生成素(EPO)联合化疗治疗癌症相关性贫血 被引量:4

Treatment of Malignant Tumor Anemia (MTA) by Erythropoietin (EPO) Combined with Chemotherapy
下载PDF
导出
摘要 目的 :恶性肿瘤化疗的同时联合应用促红细胞生成素 (EPO) ,观察对癌症相关性贫血 (MTA)临床症状的改善效果。方法 :观察组在化疗前 1周开始给予EPO ,对照组只进行化疗不用EPO ,其他辅助治疗两组相同 (包括营养支持、粒细胞刺激因子应用、出血者止血药物的应用、重要脏器的保护等 )。结果与结论 :化疗联合用EPO能预防和治疗MTA。对靠输血提升血红蛋白后化疗的患者可明显减少输血量 ,甚至可停止输血。 OBJECTIVE:To observe the result of improvement on clinical symptom of MTA by malignant tumor chemotherapy combined with EPO.METHODS: Observing grou p began to use EPO one week before chemotherapy, control group only perform che motherapy without EPO, other adjunctive therapy in two groups were same (includ ing nutritional support, use of granulocyte stimulating factor, anastaltic for the patients with hemorrhage and protection of important organs).RESULTS & CO NCLUSION:Chemotherapy combined with EPO can prevent and treat MTA, obviously decrease blood transfusion quantity in the patients depending on blood transfusi on to increase hemoglobin during chemotherapy and even stop blood transfusion. EPO has certain effect on treatment of MTA and prevention of anemia caused by ch emotherapy.
出处 《中国医院用药评价与分析》 2003年第6期354-355,共2页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 促红细胞生成素 EPO 联合化疗 癌症相关性贫血 MTA 恶性肿瘤 临床研究 病例分析 erythropoietin (EPO) malignant tumor malignant tumor anemia
  • 相关文献

参考文献1

二级参考文献27

  • 1钱家麒.重组人促红细胞生成素应用中的新问题-纯红再障.中国医学论坛报,2003,2(13):8-8.
  • 2Stein R S.Abels R l.Krantz S B. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes [J]. Blood,1991,78: 1658-- 1663.
  • 3Dan L L,Howard H G,Louise B G,et al. Pathophysiology and manifestation of myeloma[J]. MKSAP (oncology),2001,53--55.
  • 4Littlewood T J. Erythropoietin for the treatment of anemia associated with hemotological malignancy [J]. Hematol Oncol.2001.19 : 19-- 30.
  • 5Miyke T, Kung K M, Goldwassere. Purification of human erythropoietin[J]. J Biol Chem, 1977,252:5568-- 5588.
  • 6Krantz S B. Erythopoietin [J]. Blood,1991,77:419-- 422.
  • 7Spovak J L, Recombinant human erythropoietin and the anemia of cancer[J ]. Blood, 1994,84:997--1004.
  • 8Miller C B, Jones R J, Piantadosi S,et al. Decreased erythropoietin response in patients with the anemia of cancer[J]. N Engl J Med, 1990,322 : 1689-- 1691.
  • 9Coffier B. Anemia associated with non-platinum chemotherapy ( CT ) for Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL) [J]. ECCO.1999.35:19-- 22.
  • 10Henry D H,Abels R I. Recombinant human erythropoietin in the treatment of cancer and chemotherapy. Induced anemia:results of double-blind and open-la-bel fellow-up studies [J]. Seminars in Oncology, 1994,21 : 21 -- 28.

共引文献5

同被引文献30

  • 1周明,王远东,韩国栋,陈贵全,李洪胜.促红细胞生成素在食管癌患者中的应用[J].岭南现代临床外科,2004,4(2):131-132. 被引量:12
  • 2管忠震,张力,李龙芸,蒋国梁,刘叙仪,储大同,赵洪云,李玮.吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究[J].癌症,2005,24(8):980-984. 被引量:114
  • 3邝贺龄主编.内科疾病鉴别诊断学(第3版)[M]. 北京:人民卫生出版社,1994,506
  • 4Auperin A, Le Pechoux C, Rolland E, et al. Meta - analysis of concomitantversus sequential radiochemotherapy in locally advancednon-small-eell lung cancer [J]. J Clin Oncol, 2010,28 : 2181-2190.
  • 5Rowell NP,O'rourke NP. Concurrent chemoradiotherapy in non- small cell lung cancer[J]. Cochrane Database Syst Rev, 2004,4 : 2140.
  • 6张曼,陶秀娟.非小细胞肺癌的生物治疗研究进展[J].安徽医药,2012,16(7):1008-1010.
  • 7D Lee, SKim, K Park, et al. A randomized open-label studyof gefitinib versus docetaxel in patients with advanced / metastaticnon-small cell lung cancer (NSCLC) who have previously receivedplatinum -based chemotherapy [J].Journal of Clinical Oneology, 2008,26 : 8025.
  • 8李雅、常红莉等.吉非替尼靶向治疗中晚期非小细胞肺癌40例,2015,09(02).
  • 9WorlD Health Organization. Cancer. Available at: http://www, who. int/mediacentre/factsheets/fs297/en/index. html. Accessed December 21, 2010.
  • 10Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部